Nvidia (NVDA) Stock Analysis for Today
TradeCompass: Nvidia (NVDA) Stock Analysis – 15 January 2025 Financial Instrument: Nvidia Stock (NVDA) Price at the Time of Analysis: […]
January 15, 2025
Trump’s SEC to revise crypto policies reshaping enforcement rules
Photo: Inc. Magazine Key Takeaways Republican SEC commissioners plan to review crypto enforcement cases and clarify the definition of securities.
Whales Propel XRP To The Top Again
16h28 ▪ 3 min read ▪ by Mikaia A. Ripple and its crypto, XRP, have recently left part of their
Thailand navigates crypto with Bitcoin ETF ambitions and Polymarket scrutiny
Thailand is ramping up its involvement in the crypto space with two contrasting regulatory moves. Media reports in the Asian
the company behind the largest ever illicit online marketplace has launched a stablecoin
Huione Guarantee is a Telegram-based marketplace serving fraudsters in South East Asia, including those responsible for so-called “pig butchering” scams.
biotech’s lung cancer drug stock shows promise amid risks By Investing.com
Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biotechnology company valued at $5.1 billion, has been making waves in the oncology space with
Why Crypto Whales Are Rushing to Buy Dogecoin, XRP, Ethereum, PlutoChain, and Cardano Before Trump’s Inauguration
As Trump’s inauguration approaches, market participants are closely watching Dogecoin, XRP, Ethereum, Cardano, and PlutoChain. Trump’s pro-crypto stance, including plans
Snap stock price target cut, outperform rating on growth potential By Investing.com
On Wednesday, BMO Capital Markets adjusted its outlook on shares of Snap Inc (NYSE: NYSE:), reducing the price target from
Crypto in 2025: A Growing Fixture of Global Geopolitics
Over the past 15 years, cryptocurrency has evolved from a niche experiment in digital payments to a global financial juggernaut,
Goldman Sachs holds Tarsus stock price target, strong buy rating By Investing.com
On Wednesday, Goldman Sachs reiterated a Neutral rating with a steady $41.00 price target on shares of Tarsus Pharmaceuticals (NASDAQ:TARS),